Do analysts recommend RLYB or AMRN?

Amarin has a consensus target price of $12.00, suggesting a potential downside of 17.01%. Given Amarin's stronger consensus rating and higher possible upside, analysts plainly believe Amarin is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33

Which has better earnings and valuation, RLYB or AMRN?

Rallybio has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rallybio $860K 104.31 -$8.98M -$4.34 N/A Amarin $213.65M 1.42 -$38.80M -$0.65 N/A

Is RLYB or AMRN more profitable?

Amarin has a net margin of -15.51% compared to Rallybio's net margin of -911.07%. Amarin's return on equity of -2.99% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -55.79% -51.48% Amarin -15.51% -2.99% -2.07%

Does the media prefer RLYB or AMRN?

In the previous week, Rallybio had 1 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Rallybio and 4 mentions for Amarin. Amarin's average media sentiment score of 0.95 beat Rallybio's score of 0.92 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SLN or RLYB?

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 746.28%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to SLN or RLYB?

In the previous week, Rallybio had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Rallybio and 3 mentions for Silence Therapeutics. Rallybio's average media sentiment score of 0.92 beat Silence Therapeutics' score of 0.62 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RGNX or RLYB?

REGENXBIO presently has a consensus target price of $23.91, suggesting a potential upside of 228.42%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score REGENXBIO 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, RGNX or RLYB?

Rallybio has lower revenue, but higher earnings than REGENXBIO. Rallybio is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.21 -$193.88M -$5.60 N/A Rallybio $860K 104.31 -$8.98M -$4.34 N/A

Is RGNX or RLYB more profitable?

REGENXBIO has a net margin of -330.23% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -330.23% -232.50% -61.02% Rallybio -911.07% -55.79% -51.48%

Does the media favor RGNX or RLYB?

In the previous week, Rallybio had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Rallybio and 3 mentions for REGENXBIO. Rallybio's average media sentiment score of 0.92 beat REGENXBIO's score of 0.85 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NAGE or RLYB?

Niagen Bioscience presently has a consensus price target of $14.67, indicating a potential upside of 302.38%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, NAGE or RLYB?

Niagen Bioscience has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 2.24 $17.38M $0.21 17.36 Rallybio $860K 104.31 -$8.98M -$4.34 N/A

Does the media favor NAGE or RLYB?

In the previous week, Rallybio had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Rallybio and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.14 beat Rallybio's score of 0.92 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FBRX or RLYB?

Forte Biosciences currently has a consensus price target of $67.00, suggesting a potential upside of 247.85%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Trading of Rallybio was halted at 07:55 AM EST due to "News Pending".

Rallybio (RLYB) Competitors

$16.92 +2.47 (+17.05%)

As of 03:08 PM Eastern

Compare

RLYB vs. AMRN, SLN, RGNX, NAGE, and FBRX

Should you buy Rallybio stock or one of its competitors? MarketBeat compares Rallybio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rallybio include Amarin (AMRN), Silence Therapeutics (SLN), REGENXBIO (RGNX), Niagen Bioscience (NAGE), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry.

How does Rallybio compare to Amarin?

Rallybio (NASDAQ:RLYB) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Amarin has a net margin of -15.51% compared to Rallybio's net margin of -911.07%. Amarin's return on equity of -2.99% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Amarin	-15.51%	-2.99%	-2.07%

Rallybio has a beta of -0.89, meaning that its share price is 189% less volatile than the broader market. Comparatively, Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Rallybio had 1 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Rallybio and 4 mentions for Amarin. Amarin's average media sentiment score of 0.95 beat Rallybio's score of 0.92 indicating that Amarin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rallybio has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.31	-$8.98M	-$4.34	N/A
Amarin	$213.65M	1.42	-$38.80M	-$0.65	N/A

Amarin has a consensus target price of $12.00, suggesting a potential downside of 17.01%. Given Amarin's stronger consensus rating and higher possible upside, analysts plainly believe Amarin is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Amarin beats Rallybio on 9 of the 15 factors compared between the two stocks.

How does Rallybio compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Rallybio had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Rallybio and 3 mentions for Silence Therapeutics. Rallybio's average media sentiment score of 0.92 beat Silence Therapeutics' score of 0.62 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rallybio has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	548.24	-$88.61M	-$1.59	N/A
Rallybio	$860K	104.31	-$8.98M	-$4.34	N/A

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rallybio has a net margin of -911.07% compared to Silence Therapeutics' net margin of -8,943.86%. Rallybio's return on equity of -55.79% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Rallybio	-911.07%	-55.79%	-51.48%

Silence Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, suggesting that its share price is 189% less volatile than the broader market.

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 746.28%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Rallybio beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Rallybio compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Rallybio has lower revenue, but higher earnings than REGENXBIO. Rallybio is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.21	-$193.88M	-$5.60	N/A
Rallybio	$860K	104.31	-$8.98M	-$4.34	N/A

REGENXBIO has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, suggesting that its share price is 189% less volatile than the broader market.

REGENXBIO presently has a consensus target price of $23.91, suggesting a potential upside of 228.42%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

REGENXBIO has a net margin of -330.23% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Rallybio	-911.07%	-55.79%	-51.48%

In the previous week, Rallybio had 2 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Rallybio and 3 mentions for REGENXBIO. Rallybio's average media sentiment score of 0.92 beat REGENXBIO's score of 0.85 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

REGENXBIO and Rallybio tied by winning 8 of the 16 factors compared between the two stocks.

How does Rallybio compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Niagen Bioscience has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.24	$17.38M	$0.21	17.36
Rallybio	$860K	104.31	-$8.98M	-$4.34	N/A

Niagen Bioscience presently has a consensus price target of $14.67, indicating a potential upside of 302.38%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Niagen Bioscience has a net margin of 14.29% compared to Rallybio's net margin of -911.07%. Niagen Bioscience's return on equity of 22.68% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Rallybio	-911.07%	-55.79%	-51.48%

Niagen Bioscience has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, meaning that its stock price is 189% less volatile than the broader market.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Rallybio had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 5 mentions for Rallybio and 2 mentions for Niagen Bioscience. Niagen Bioscience's average media sentiment score of 1.14 beat Rallybio's score of 0.92 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Niagen Bioscience beats Rallybio on 12 of the 16 factors compared between the two stocks.

How does Rallybio compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Rallybio had 4 more articles in the media than Forte Biosciences. MarketBeat recorded 5 mentions for Rallybio and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat Rallybio's score of 0.92 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Very Positive
Rallybio	Positive

Forte Biosciences has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, meaning that its share price is 189% less volatile than the broader market.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rallybio has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Rallybio	$860K	104.31	-$8.98M	-$4.34	N/A

Forte Biosciences currently has a consensus price target of $67.00, suggesting a potential upside of 247.85%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Forte Biosciences has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Rallybio	-911.07%	-55.79%	-51.48%

Summary

Rallybio beats Forte Biosciences on 9 of the 15 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLYB vs. The Competition

Export

Metric	Rallybio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$89.71M	$3.33B	$6.32B	$12.64B
Dividend Yield	N/A	2.28%	2.68%	5.31%
P/E Ratio	-3.90	18.16	21.14	26.75
Price / Sales	104.31	329.99	548.19	115.38
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	1.54	6.86	9.92	6.92
Net Income	-$8.98M	$24.15M	$3.56B	$336.84M
7 Day Performance	6.58%	2.36%	2.24%	4.33%
1 Month Performance	N/A	N/A	N/A	-0.37%
1 Year Performance	574.20%	63.67%	36.82%	40.73%

Rallybio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLYB Rallybio	1.7329 of 5 stars	$16.93 +17.0%	N/A	+476.0%	$89.71M	$860K	N/A	40	News Coverage Positive News Short Interest Decrease Gap Up Trading Halted
AMRN Amarin	1.4252 of 5 stars	$14.05 -0.1%	$12.00 -14.6%	+24.9%	$294.83M	$213.65M	N/A	360
SLN Silence Therapeutics	3.0059 of 5 stars	$5.77 -7.4%	$55.00 +853.2%	+16.9%	$294.27M	$560K	N/A	100
RGNX REGENXBIO	3.4095 of 5 stars	$5.66 +0.2%	$23.91 +322.4%	-19.2%	$292.61M	$87.82M	N/A	370
NAGE Niagen Bioscience	4.4589 of 5 stars	$3.66 -1.1%	$14.67 +300.7%	-64.3%	$292.29M	$130.42M	17.43	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLYB) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rallybio (RLYB) Competitors

RLYB vs. AMRN, SLN, RGNX, NAGE, and FBRX

How does Rallybio compare to Amarin?

Summary

How does Rallybio compare to Silence Therapeutics?

Summary

How does Rallybio compare to REGENXBIO?

Summary

How does Rallybio compare to Niagen Bioscience?

Summary

How does Rallybio compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rallybio (RLYB) Competitors

RLYB vs. AMRN, SLN, RGNX, NAGE, and FBRX

How does Rallybio compare to Amarin?

Is RLYB or AMRN more profitable?

Which has more volatility and risk, RLYB or AMRN?

Do institutionals and insiders hold more shares of RLYB or AMRN?

Does the media prefer RLYB or AMRN?

Which has better earnings and valuation, RLYB or AMRN?

Do analysts recommend RLYB or AMRN?

Summary

How does Rallybio compare to Silence Therapeutics?

Does the media refer more to SLN or RLYB?

Which has preferable valuation & earnings, SLN or RLYB?

Do institutionals & insiders believe in SLN or RLYB?

Is SLN or RLYB more profitable?

Which has more risk and volatility, SLN or RLYB?

Do analysts rate SLN or RLYB?

Summary

How does Rallybio compare to REGENXBIO?

Which has preferable earnings and valuation, RGNX or RLYB?

Which has more volatility & risk, RGNX or RLYB?

Do analysts recommend RGNX or RLYB?

Is RGNX or RLYB more profitable?

Does the media favor RGNX or RLYB?

Do institutionals & insiders hold more shares of RGNX or RLYB?

Summary

How does Rallybio compare to Niagen Bioscience?

Which has stronger valuation and earnings, NAGE or RLYB?

Do analysts prefer NAGE or RLYB?

Is NAGE or RLYB more profitable?

Which has more volatility & risk, NAGE or RLYB?

Do insiders and institutionals believe in NAGE or RLYB?

Does the media favor NAGE or RLYB?

Summary

How does Rallybio compare to Forte Biosciences?

Does the media favor FBRX or RLYB?

Which has more volatility and risk, FBRX or RLYB?

Do insiders & institutionals hold more shares of FBRX or RLYB?

Which has better valuation and earnings, FBRX or RLYB?

Do analysts rate FBRX or RLYB?

Is FBRX or RLYB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools